HUP0400006A2 - Antineopláziás kombinációs készítmények - Google Patents

Antineopláziás kombinációs készítmények

Info

Publication number
HUP0400006A2
HUP0400006A2 HU0400006A HUP0400006A HUP0400006A2 HU P0400006 A2 HUP0400006 A2 HU P0400006A2 HU 0400006 A HU0400006 A HU 0400006A HU P0400006 A HUP0400006 A HU P0400006A HU P0400006 A2 HUP0400006 A2 HU P0400006A2
Authority
HU
Hungary
Prior art keywords
antineoplastic combinations
antineoplastic
combinations
Prior art date
Application number
HU0400006A
Other languages
English (en)
Hungarian (hu)
Inventor
Gary Dukart
James Joseph Gibbons Jr.
Original Assignee
Wyeth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth filed Critical Wyeth
Publication of HUP0400006A2 publication Critical patent/HUP0400006A2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU0400006A 2001-06-01 2002-05-29 Antineopláziás kombinációs készítmények HUP0400006A2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29523601P 2001-06-01 2001-06-01
US29519001P 2001-06-01 2001-06-01
PCT/US2002/016737 WO2002098416A2 (en) 2001-06-01 2002-05-29 Antineoplastic combinations

Publications (1)

Publication Number Publication Date
HUP0400006A2 true HUP0400006A2 (hu) 2004-04-28

Family

ID=26968972

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400006A HUP0400006A2 (hu) 2001-06-01 2002-05-29 Antineopláziás kombinációs készítmények

Country Status (17)

Country Link
EP (1) EP1392286A2 (cg-RX-API-DMAC7.html)
JP (1) JP2004532883A (cg-RX-API-DMAC7.html)
KR (1) KR100875611B1 (cg-RX-API-DMAC7.html)
CN (1) CN100496485C (cg-RX-API-DMAC7.html)
AU (2) AU2002259309B2 (cg-RX-API-DMAC7.html)
BR (1) BR0210101A (cg-RX-API-DMAC7.html)
CA (1) CA2447732A1 (cg-RX-API-DMAC7.html)
CO (1) CO5540294A2 (cg-RX-API-DMAC7.html)
EA (1) EA007530B1 (cg-RX-API-DMAC7.html)
HU (1) HUP0400006A2 (cg-RX-API-DMAC7.html)
IL (1) IL158800A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA03010907A (cg-RX-API-DMAC7.html)
NO (1) NO20035317L (cg-RX-API-DMAC7.html)
NZ (1) NZ529877A (cg-RX-API-DMAC7.html)
PL (1) PL367267A1 (cg-RX-API-DMAC7.html)
SG (1) SG153647A1 (cg-RX-API-DMAC7.html)
WO (1) WO2002098416A2 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL231418B1 (pl) 2001-02-19 2019-02-28 Novartis Ag 40-O-( 2-hydroksyetylo)- rapamycyna do zastosowania w leczeniu guzów litych płuc, innych niż nowotwór tkanki limfatycznej
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
AR046194A1 (es) 2003-11-04 2005-11-30 Mayo Foundation Metodo de tratamiento del linfoma de celulas del manto
MX2007009317A (es) 2005-02-03 2008-01-30 Gen Hospital Corp Metodo para tratar cancer resistente a gefitinib.
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
GB0523658D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
JP2009516671A (ja) * 2005-11-21 2009-04-23 ノバルティス アクチエンゲゼルシャフト ｍＴＯＲ阻害剤を使用する神経内分泌腫瘍処置
US20090023768A1 (en) * 2006-02-24 2009-01-22 Novartis Ag Rapamycin derivatives for treating neuroblastoma
KR20140019032A (ko) * 2006-04-05 2014-02-13 노파르티스 아게 암을 치료하기 위한 치료제의 조합물
MX380318B (es) * 2007-03-07 2025-03-12 Abraxis Bioscience Llc Nanoparticula que comprende rapamicina y albumina como agente anticancer.
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
WO2010008744A2 (en) 2008-06-17 2010-01-21 Wyeth Antineoplastic combinations containing hki-272 and vinorelbine
RU2498804C2 (ru) 2008-08-04 2013-11-20 ВАЙЕТ ЭлЭлСи Противоопухолевые комбинации из 4-анилино-3-цианохинолинов и капецитабина
JP5992325B2 (ja) 2009-04-06 2016-09-14 ワイス・エルエルシー 乳癌のための、ネラチニブを活用する治療計画
CN103721189A (zh) * 2013-12-27 2014-04-16 刘玉含 一种脑膜瘤护理药物及其制备方法
CN105168204A (zh) * 2015-09-06 2015-12-23 江志鑫 一种含有丝裂霉素的抗结肠癌药物组合物
CN119732959A (zh) * 2024-12-31 2025-04-01 吉林大学 具有mTOR抑制能力的制剂在制备抗肿瘤联合用药物组合物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4401653A (en) * 1981-03-09 1983-08-30 Ayerst, Mckenna & Harrison Inc. Combination of rapamycin and picibanil for the treatment of tumors
DE69209183T2 (de) * 1991-06-18 1996-08-08 American Home Prod Verwendung von Rapamycin zur Behandlung von T-Zellen Lymphom/Leukämie bei Erwachsenen
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
PL231418B1 (pl) * 2001-02-19 2019-02-28 Novartis Ag 40-O-( 2-hydroksyetylo)- rapamycyna do zastosowania w leczeniu guzów litych płuc, innych niż nowotwór tkanki limfatycznej

Also Published As

Publication number Publication date
EP1392286A2 (en) 2004-03-03
CO5540294A2 (es) 2005-07-29
PL367267A1 (en) 2005-02-21
AU2002259309B2 (en) 2008-05-01
AU2008202690A1 (en) 2008-07-10
EA200301319A1 (ru) 2004-04-29
NO20035317L (no) 2003-12-22
KR20040025923A (ko) 2004-03-26
MXPA03010907A (es) 2004-02-17
CN1646120A (zh) 2005-07-27
NZ529877A (en) 2006-08-31
CA2447732A1 (en) 2002-12-12
WO2002098416A3 (en) 2003-03-13
JP2004532883A (ja) 2004-10-28
CN100496485C (zh) 2009-06-10
WO2002098416A2 (en) 2002-12-12
KR100875611B1 (ko) 2008-12-24
EA007530B1 (ru) 2006-10-27
IL158800A0 (en) 2004-05-12
SG153647A1 (en) 2009-07-29
BR0210101A (pt) 2004-06-08
NO20035317D0 (no) 2003-11-28

Similar Documents

Publication Publication Date Title
IL159859A0 (en) Antineoplastic combinations
IL160851A0 (en) Thiopene-and thiazolesulfonamides as antineoplastic agents
DE60141364D1 (en) Polyphenylensulfidharzzusammensetzung
DE60141362D1 (en) Ösophagus-stoma-knopf
ZA200603888B (en) Antineoplastic combinations
IL158800A0 (en) Antineoplastic combinations
GB0102319D0 (en) Light-diffuser
DE50214962D1 (en) Heterocyclylarylsulfonamide
DE60206072D1 (en) Aroylpyridinone
DE60236364D1 (en) Hepatitis-c-virus-impfstoff
EP1355643A4 (en) EPOXYVIBSANIN B
GB0117479D0 (en) Jetters
CA93647S (en) Fauteuil
CA93646S (en) Fauteuil
CA93959S (en) Tilt-latch
EG22913A (en) Anometer
HK1060846A (en) Antineoplastic combinations
GB0110942D0 (en) Vita-tea
GB0103266D0 (en) Ditractor
GB0113029D0 (en) Storet
GB0109895D0 (en) Portadam
GB0108173D0 (en) Helmlight
GB0107567D0 (en) Visor-demister
GB0106702D0 (en) Reactor-vision
GB0106128D0 (en) Easiknees

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees